Drug Profile
Research programme: proto oncogene protein c-myc inhibitors - Sorrento Therapeutics
Latest Information Update: 25 Apr 2023
Price :
$50
*
At a glance
- Originator The Scripps Research Institute
- Developer Sorrento Therapeutics; The Scripps Research Institute
- Class Small molecules
- Mechanism of Action Proto oncogene protein c-myc inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Apr 2023 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 28 Sep 2018 No recent reports of development identified for preclinical development in Cancer in USA
- 18 Aug 2014 Preclinical trials in Cancer in USA (unspecified route) prior to August 2014